keyword
MENU ▼
Read by QxMD icon Read
search

Paritaprevir

keyword
https://www.readbyqxmd.com/read/29210779/remarkable-plasma-hiv-rna-decrease-by-ombitasvir-paritaprevir-ritonavir-in-an-hiv-hcv-coinfection-case
#1
Yukihiro Yoshimura, Nobuyuki Miyata, Hirokazu Komatsu, Natsuo Tachikawa
No abstract text is available yet for this article.
January 2, 2018: AIDS
https://www.readbyqxmd.com/read/29194858/low-incidence-of-hepatitis-b-virus-reactivation-and-subsequent-hepatitis-in-patients-with-chronic-hepatitis-c-receiving-direct-acting-antiviral-therapy
#2
Akihiro Tamori, Seigo Abiru, Hirayuki Enomoto, Kiyohide Kioka, Masaaki Korenaga, Joji Tani, Masaru Enomoto, Masaya Sugiyama, Tsutomu Masaki, Norifumi Kawada, Hiroshi Yatsuhashi, Shuhei Nishiguchi, Masashi Mizokami
To determine the clinical characteristics of hepatitis B virus (HBV) reactivation in patients undergoing interferon-free anti-hepatitis C virus (HCV) therapy, we examined HBV DNA in 25 HBV co-infected patients and 765 patients with resolved HBV infection during and after treatment with direct-acting antiviral agents (DAAs). Among those with HCV genotype 1, asunaprevir plus daclatasvir was administered to 160 patients, sofosbuvir (SOF) plus ledipasvir to 438 patients, and paritaprevir plus ombitasvir and ritonavir to 25 patients...
November 30, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/29146520/patterns-of-resistance-associated-substitutions-in-patients-with-chronic-hcv-infection-following-treatment-with-direct-acting-antivirals
#3
Julia Dietz, Simone Susser, Johannes Vermehren, Kai-Henrik Peiffer, Georgios Grammatikos, Annemarie Berger, Peter Ferenci, Maria Buti, Beat Müllhaupt, Bela Hunyady, Holger Hinrichsen, Stefan Mauss, Jörg Petersen, Peter Buggisch, Gisela Felten, Dietrich Hüppe, Gaby Knecht, Thomas Lutz, Eckart Schott, Christoph Berg, Ulrich Spengler, Thomas von Hahn, Thomas Berg, Stefan Zeuzem, Christoph Sarrazin
BACKGROUND & AIMS: Little is known about substitutions that mediate resistance of HCV to direct-acting antivirals (DAAs), due to the small number of patients with treatment failure in approval studies. It is important to identify resistance patterns to select effective salvage treatments. METHODS: We performed a comprehensive analysis for resistance-associated substitutions (RASs) in HCV genes (NS3, NS5A, NS5B) targeted by DAAs. We compared NS3, NS5A, and NS5B sequences from 626 patients in Europe with DAA failure with sequences from 2322 DAA-naïve patients, infected with HCV genotypes 1-4...
November 13, 2017: Gastroenterology
https://www.readbyqxmd.com/read/29145802/effectiveness-of-current-and-future-regimens-for-treating-genotype-3-hepatitis-c-virus-infection-a-large-scale-systematic-review
#4
Hosnieh Fathi, Andrew Clark, Nathan R Hill, Geoffrey Dusheiko
BACKGROUND: Six distinct genetic variants (genotypes 1 - 6) of hepatitis C virus (HCV) exist globally. Certain genotypes are more prevalent in particular countries or regions than in others but, globally, genotype 3 (GT3) is the second most common. Patients infected with HCV GT1, 2, 4, 5 or 6 recover to a greater extent, as measured by sustained virological response (SVR), following treatment with regimens based on direct-acting antivirals (DAAs) than after treatment with older regimens based on pegylated interferon (Peg-IFN)...
November 16, 2017: BMC Infectious Diseases
https://www.readbyqxmd.com/read/29126346/paritaprevir-ritonavir-ombitasvir-plus-dasabuvir-therapy-related-severe-anemia
#5
Hayretdin Koklu, Tuğrul Pürnak, Nomingerel Tseveldorj, Ege Altan, Halis Şimşek
No abstract text is available yet for this article.
November 1, 2017: Annals of Pharmacotherapy
https://www.readbyqxmd.com/read/29106584/plasma-trough-concentrations-of-antiretrovirals-in-hiv-infected-persons-treated-with-direct-acting-antiviral-agents-for-hepatitis-c-in-the-real-world
#6
Massimo Tempestilli, Gabriele Fabbri, Ilaria Mastrorosa, Laura Timelli, Stefania Notari, Rita Bellagamba, Raffaella Libertone, Federico Lupi, Mauro Zaccarelli, Andrea Antinori, Chiara Agrati, Adriana Ammassari
Background: Possible drug-drug interactions (DDIs) between antiretrovirals (ARVs) and direct-acting antiviral agents (DAAs) are of some concern. Objectives: To investigate ARV plasma trough concentrations (Ctrough) before and during DAAs in patients treated in the real world. Methods: Single-centre, prospective, observational study including HIV/HCV coinfected persons undergoing DAA treatment. Self-reported adherence was assessed and ARVs Ctrough measured by HPLC-UV...
November 2, 2017: Journal of Antimicrobial Chemotherapy
https://www.readbyqxmd.com/read/29098140/mpgn-and-mixed-cryoglobulinemia-in-a-patient-with-hepatitis-c-new-treatment-implications-and-renal-outcomes
#7
Shannon B Palombo, Eric C Wendel, Laura R Kidd, Farshid Yazdi, Mihran V Naljayan
. INTRODUCTION: The association of hepatitis C virus (HCV), cryoglobulinemia, and membranoproliferative glomerulonephritis (MPGN) is well known. Treatment of underlying HCV infection has greatly improved in recent years with the introduction of direct-acting antivirals (DAA), which have demonstrated curative sustained viral response (SVR) rates for select viral genotypes with the added benefit of less drug side effects. However, a mainstay of newer DAAs is sofosbuvir, which is contraindicated in patients with severe renal impairment...
2017: Clinical Nephrology. Case Studies
https://www.readbyqxmd.com/read/29062907/ombitasvir-paritaprevir-ritonavir-dasabuvir-%C3%A2-ribavirin-for-treatment-of-chronic-hepatitis-c-1-genotype-in-the-republic-of-belarus
#8
Dzmitry Danilau, Nadzeya Malich, Dzmitry Litvinchuk, Igor Karpov
AIM OF THE STUDY: Aim of the study is to evaluate real-world efficacy of the ombitasvir/ paritaprevir/ ritonavir + dasabuvir ± ribavirin for treatment of chronic hepatitis C 1 genotype. MATERIAL AND METHODS: The study included 27 patients according to inclusion criteria. Main laboratory studies were performed in all patients at the baseline and during the treatment. RESULTS: Efficacy of the antiviral therapy was assessed by measuring the SVR12 and the SVR24 along with measuring of viral load during the treatment...
September 2017: Clin Exp Hepatol
https://www.readbyqxmd.com/read/29050674/the-outcomes-of-glucose-abnormalities-in-chronic-hepatitis-c-patients-receiving-interferon-free-direct-antiviral-agents
#9
Jee-Fu Huang, Chung-Feng Huang, Ming-Lun Yeh, Chia-Yen Dai, Meng-Hsuan Hsieh, Jeng-Fu Yang, Ching-I Huang, Yi-Hung Lin, Po-Cheng Liang, Zu-Yau Lin, Shinn-Chern Chen, Ming-Lung Yu, Wan-Long Chuang
Direct-acting antiviral agents (DAAs) have been widely used for chronic hepatitis C (CHC) treatment recently. The characteristics of glucose abnormalities after DAAs therapy however, remain elusive. We aimed to elucidate the mutual impact between treatment response and parameters of glucose abnormalities after DAAs therapy in CHC patients. CHC patients who received DAAs therapy were recruited. The primary outcome measurements were their insulin resistance (IR) and beta-cell function assessed by the homeostasis model assessment (HOMA) method before treatment and at end-of-follow-up (EOF)...
November 2017: Kaohsiung Journal of Medical Sciences
https://www.readbyqxmd.com/read/29049126/shear-wave-elastography-for-the-assessment-of-liver-fibrosis-in-liver-transplant-recipients-treated-for-hepatitis-c-virus-recurrence
#10
David Korda, Zsuzsanna M Lenard, Zsuzsanna Gerlei, Zsuzsanna Jakab, Anita Haboub-Sandil, Laszlo Wagner, Marina Varga, Orsolya Cseprekal, Adrienn Marton, Denes Horvathy, Szabolcs Takacs, Attila Doros, Zoltan Mathe
OBJECTIVES: Direct-acting antiviral agents have revolutionized hepatitis C therapy, and are also found to be effective in the liver transplant setting. The extent of liver fibrosis influences patient management and is used to monitor therapeutic effects. Shear-wave elastography (SWE) is a relatively new imaging-based method that has not yet been studied extensively in liver transplant patients. Our aim was to study the effect of direct-acting antivirals in heaptitis C recurrence on liver stiffness determined by SWE...
October 18, 2017: European Journal of Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/28994141/potential-drug-drug-interactions-of-ombitasvir-paritaprevir-ritonavir-%C3%A2-dasabuvir-%C3%A2-ribavirin-in-clinical-practice
#11
Elena González-Colominas, María-Carlota Londoño, Rosa M Morillas, Xavier Torras, Sergi Mojal, Sabela Lens, Dulce López, Adolfo Gallego, Zoe Mariño, Mercè Ardèvol, Neus Pagès, Ricard Solà, Jose A Carrión
BACKGROUND & AIMS: Drug-drug interactions (DDIs) with ombitasvir/paritaprevir/ritonavir with or without dasabuvir and with or without ribavirin (OBV/PTV/r ± DSV ± RBV) are common in clinical trials. Our aim was to analyze the prevalence and management of potential DDIs and adverse events (AEs) related to DDIs in patients with chronic hepatitis C (CHC) receiving OBV/PTV/r ± DSV ± RBV in clinical practice. METHODS: 177 CHC patients started OBV/PTV/r ± DSV ± RBV in 4 Spanish hospitals and were screened for potential DDIs using the University of Liverpool database...
October 10, 2017: Journal of Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/28992878/peginterferon-alfa-2a-for-the-treatment-of-chronic-hepatitis-c-in-the-era-of-direct-acting-antivirals
#12
REVIEW
Yan Huang, Ming-Hui Li, Min Hou, Yao Xie
BACKGROUND: The availability of novel direct-acting antivirals (DAAs) represents a new era of curative hepatitis C virus (HCV) treatment, with over 95% of patients infected with HCV genotype 1 achieving sustained virological response (SVR). Nevertheless, the majority of patients globally are unable to access these treatments because of cost and infrastructure constraints and, thus, remain untreated and uncured. DATA SOURCE: Relevant articles of peginterferon (PegIFN)-based treatments in HCV and sofosbuvir-based treatments, simeprevir, daclatasvir/asunaprevir, ritonavir-boosted paritaprevir/ombitasvir/dasabuvir, and grazoprevir/elbasvir, were searched in PubMed database, including general population and special population...
October 15, 2017: Hepatobiliary & Pancreatic Diseases International: HBPD INT
https://www.readbyqxmd.com/read/28990653/mechanism-of-in-vitro-inhibition-of-ugt1a1-by-paritaprevir
#13
Novera Alam, Mia G Angeli, David J Greenblatt
OBJECTIVES: The direct-acting protease inhibitor paritaprevir is a new pharmaco-logic option available for treatment of chronic hepatitis C (HCV). Paritaprevir is reported to inhibit human UGT 1A1, but the mechanism of inhibition and its possible clinical consequences are not established. Our objective was to evaluate the in-vitro metabolic interaction between paritaprevir and the oral contraceptive steroid ethinyl estradiol (EE), a UGT 1A1 substrate. METHODS: Enzyme kinetic parameters were determined using human liver microsomes for the biotransformation of EE to its glucuronide metabolites, and the potency and mechanism of inhibition by paritaprevir...
October 9, 2017: Journal of Pharmacy and Pharmacology
https://www.readbyqxmd.com/read/28986139/restrictions-for-reimbursement-of-interferon-free-direct-acting-antiviral-drugs-for-hcv-infection-in-europe
#14
Alison D Marshall, Evan B Cunningham, Stine Nielsen, Alessio Aghemo, Hannu Alho, Markus Backmund, Philip Bruggmann, Olav Dalgard, Carole Seguin-Devaux, Robert Flisiak, Graham R Foster, Liana Gheorghe, David Goldberg, Ioannis Goulis, Matthew Hickman, Patrick Hoffmann, Ligita Jancorienė, Peter Jarcuska, Martin Kåberg, Leondios G Kostrikis, Mihály Makara, Matti Maimets, Rui Tato Marinho, Mojca Matičič, Suzanne Norris, Sigurður Ólafsson, Anne Øvrehus, Jean-Michel Pawlotsky, James Pocock, Geert Robaeys, Carlos Roncero, Marieta Simonova, Jan Sperl, Michele Tait, Ieva Tolmane, Stefan Tomaselli, Marc van der Valk, Adriana Vince, Gregory J Dore, Jeffrey V Lazarus, Jason Grebely
All-oral direct-acting antiviral drugs (DAAs) for hepatitis C virus, which have response rates of 95% or more, represent a major clinical advance. However, the high list price of DAAs has led many governments to restrict their reimbursement. We reviewed the availability of, and national criteria for, interferon-free DAA reimbursement among countries in the European Union and European Economic Area, and Switzerland. Reimbursement documentation was reviewed between Nov 18, 2016, and Aug 1, 2017. Primary outcomes were fibrosis stage, drug or alcohol use, prescriber type, and HIV co-infection restrictions...
October 3, 2017: Lancet. Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/28984012/sustained-virological-response-to-ombitasvir-paritaprevir-ritonavir-and-dasabuvir-treatment-for-hepatitis-c-real-world-data-from-a-large-healthcare-provider
#15
Clara Weil, Darshan Mehta, Gideon Koren, Brett Pinsky, Jennifer C Samp, Gabriel Chodick, Varda Shalev
Treatment with ombitasvir/paritaprevir/ritonavir and dasabuvir, with or without ribavirin (OPrD±RBV) was the first interferon-free direct-acting antiviral for hepatitis C virus (HCV) introduced to Israel's national basket of health services in February 2015. Patients with HCV genotype 1 (GT1) and advanced fibrosis (F3-F4) were eligible for treatment in 2015. This study aims to characterize patients initiating OPrD± RBV and assess sustained virological response (SVR). A retrospective cohort study was performed using the database of Maccabi Healthcare Services (MHS), a 2-million-member health plan in Israel...
October 6, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/28980064/anti-hcv-treatment-with-ombitasvir-paritaprevir-ritonavir%C3%A2-%C3%A2-dasabuvir-is-associated-with-increased-bile-acid-levels-and-pruritus
#16
Rudolf E Stauber, Günter Fauler, Florian Rainer, Bettina Leber, Andreas Posch, Andrea Streit, Walter Spindelboeck, Vanessa Stadlbauer, Harald H Kessler, Harald Mangge
BACKGROUND: Direct acting antiviral (DAA)-based treatment with ombitasvir/paritaprevir/ritonavir ± dasabuvir (OBV/PTV/r ± DSV) is highly effective in HCV genotype 1 or 4 infection and well-tolerated with only few side effects. However, pruritus has been observed in several trials in up to 20% of patients and seems to be unique for this DAA combination. OBJECTIVES: The aim of this preliminary study was to investigate the effect of OBV/PTV/r ± DSV on bile acid levels and to correlate them to the emergence of pruritus during treatment...
November 2017: Wiener Klinische Wochenschrift
https://www.readbyqxmd.com/read/28964443/cost-utility-of-elbasvir-grazoprevir-in-patients-with-chronic-hepatitis-c-genotype-1-infection
#17
COMPARATIVE STUDY
Shelby Corman, Elamin H Elbasha, Steven N Michalopoulos, Chizoba Nwankwo
OBJECTIVE: To evaluate the cost-utility of treatment with elbasvir/grazoprevir (EBR/GZR) regimens compared with ledipasvir/sofosbuvir (LDV/SOF), ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin (3D ± RBV), and sofosbuvir/velpatasvir (SOF/VEL) in patients with chronic hepatitis C genotype (GT) 1 infection. METHODS: A Markov cohort state-transition model was constructed to evaluate the cost-utility of EBR/GZR ± RBV over a lifetime time horizon from the payer perspective...
September 2017: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/28954630/multi-disciplinary-patient-centered-model-for-the-expedited-provision-of-costly-therapies-in-community-settings-the-case-of-new-medication-for-hepatitis-c
#18
Nitzan Avisar, Yael Heller, Clara Weil, Aviva Ben-Baruch, Shani Potesman-Yona, Ran Oren, Gabriel Chodick, Varda Shalev, Nachman Ash
BACKGROUND: In January 2015, the first interferon-free direct-acting antiviral (DAA) therapy for chronic hepatitis C virus (HCV) infection was approved for inclusion in Israel's national basket of health services. During 2015, HCV genotype 1 patients with advanced liver fibrosis (stage F3-F4) were eligible for treatment with ombitasvir/paritaprevir/ritonavir and dasabuvir (OMB/PTV/r + DSV) provided through the four national health plans. As all health plans committed to identifying eligible patients nationwide, risk-sharing agreements created an additional incentive to develop an innovative model for rapid treatment delivery...
September 28, 2017: Israel Journal of Health Policy Research
https://www.readbyqxmd.com/read/28948366/efficacy-and-safety-of-glecaprevir-pibrentasvir-in-japanese-patients-with-chronic-genotype-1-hepatitis-c-virus-infection-with-and-without-cirrhosis
#19
Kazuaki Chayama, Fumitaka Suzuki, Yoshiyasu Karino, Yoshiiku Kawakami, Ken Sato, Tomofumi Atarashi, Atsushi Naganuma, Tsunamasa Watanabe, Yuichiro Eguchi, Hitoshi Yoshiji, Masataka Seike, Yoshiyuki Takei, Koji Kato, Katia Alves, Margaret Burroughs, Rebecca Redman, David L Pugatch, Tami J Pilot-Matias, Preethi Krishnan, Rajneet K Oberoi, Wangang Xie, Hiromitsu Kumada
BACKGROUND: The once-daily, all oral, RBV-free, pangenotypic direct-acting anti-viral regimen consisting of co-formulated NS3/4A protease inhibitor glecaprevir and NS5A inhibitor pibrentasvir (G/P), demonstrated high rates of sustained virologic response (SVR) in phase 2 and 3 studies outside Japan. METHODS: CERTAIN-1 is a phase 3, open-label, multicenter study assessing the safety and efficacy of G/P (300/120 mg) once daily in Japanese patients with chronic HCV GT1 infection...
September 25, 2017: Journal of Gastroenterology
https://www.readbyqxmd.com/read/28948180/safety-and-efficacy-of-ombitasvir-paritaprevir-with-ritonavir-%C3%A2-dasabuvir-with-or-without-ribavirin-in-patients-with-human-immunodeficiency-virus-1-and-hepatitis-c-virus-genotype-1-or-genotype-4-coinfection-turquoise-i-part-2
#20
Jürgen K Rockstroh, Chloe Orkin, Rolando M Viani, David Wyles, Anne F Luetkemeyer, Adriano Lazzarin, Ruth Soto-Malave, Mark R Nelson, Sanjay R Bhagani, Hartwig H F Klinker, Giuliano Rizzardini, Pierre-Marie Girard, Cristina Tural, Nancy S Shulman, Niloufar Mobashery, Yiran B Hu, Linda M Fredrick, Tami Pilot-Matias, Roger Trinh, Edward Gane
BACKGROUND: Ombitasvir, paritaprevir with ritonavir, and dasabuvir (OBV/PTV/r ± DSV) ±ribavirin (RBV) are approved to treat hepatitis C virus (HCV) genotype 1 and 4 infection. Here, we investigate the safety and efficacy of OBV/PTV/r + DSV ±RBV for HCV genotype 1, and OBV/PTV/r + RBV for HCV genotype 4, in human immunodeficiency virus (HIV)-1 coinfected patients with or without compensated cirrhosis. METHODS: TURQUOISE-I, Part 2 is a phase 3 multicenter study...
2017: Open Forum Infectious Diseases
keyword
keyword
59050
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"